RT Journal Article
SR Electronic
T1 Association between antihypertensive combinations and postoperative mortality and functional decline: a nationwide survey of Japanese adults undergoing major surgeries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.14.24304265
DO 10.1101/2024.03.14.24304265
A1 Suzukawa, Rena
A1 Mandai, Shintaro
A1 Nakano, Yuta
A1 Inaba, Shunsuke
A1 Matsuki, Hisazumi
A1 Mori, Yutaro
A1 Ando, Fumiaki
A1 Mori, Takayasu
A1 Susa, Koichiro
A1 Iimori, Soichiro
A1 Naito, Shotaro
A1 Sohara, Eisei
A1 Rai, Tatemitsu
A1 Fushimi, Kiyohide
A1 Uchida, Shinichi
YR 2024
UL http://medrxiv.org/content/early/2024/03/16/2024.03.14.24304265.abstract
AB Background Considering the limited information available regarding the impact of antihypertensive classes on mortality and physical function during hospitalization, we aimed to clarify the impact of six antihypertensive classes, namely thiazide/thiazide-like diuretics (TH), calcium receptor blockers (CCBs), renin–angiotensin–aldosterone system inhibitors (RASis), mineral corticoid receptor antagonists, α-blockers, and β-blockers, on outcomes in adult patients undergoing major surgeries.Methods This study was a subanalysis of a nationwide observational cohort study involving Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database. We recruited 473,327 antihypertensive medication users and 376,583 nonusers aged ≥50 years who underwent six different types of surgeries, including coronary artery bypass grafting (CABG), thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery. The risk for overall death or functional decline, defined as a ≥5-point decrease in the Barthel Index score during hospitalization, was determined using multivariable logistic regression models.Results All-cause inhospital deaths occurred in 5,777 (1.2%) users and 2,657 (0.7%) nonusers. Functional decline was observed in 42,930 (9.2%) users and 22,550 (6.0%) nonusers. Among single class users, RASi use had a multivariable odds ratio (OR) of 0.77 (95% confidence interval (CI) 0.63–0.93 vs. TH) for the composite of mortality and functional decline. β-Blocker use was associated with an increased risk for functional decline (OR 1.27, 95% CI 1.01–1.60 vs. TH). Among the recipients of the two medication classes, TH/RASi usage was associated with the lowest risk for composite outcome (OR 0.68, 95% CI 0.60–0.77 vs. TH/CCB). Among the recipients of the three or more medication classes, TH/CCB/RASi or TH/CCB/RASi/other displayed the lowest odds for composite outcome (OR 0.72, 95% CI 0.49–0.82 vs. TH/CCB/other; OR 0.63, 95% CI 0.49–0.82 vs. TH/CCB/others). A stratified analysis revealed that RASi users had a lower OR for the composite outcome after major surgery categories except CABG than non-RASi users.Conclusions RASis were associated with decreased risk of postoperative mortality and functional decline regardless of the number of antihypertensive classes or surgery type. Managing hypertension through multidrug combinations, including RASis, may mitigate mortality and loss of physical function during the perioperative period.Clinical Perspective What is new? This nationwide observational cohort study of Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database showed that all-cause inhospital deaths occurred in 5,777 (1.2%) antihypertensive users and 2,657 (0.7%) nonusers, whereas functional decline was observed in 42,930 (9.2%) antihypertensive users and 22,550 (6.0%) nonusers.We found that an increase in the number of antihypertensive classes used, indicative of patients with treatment-resistant hypertension, was associated with a higher risk of mortality and loss of physical function, partly attributed to loop diuretic use for congestion.What are the clinical implications? This study determined combinations of antihypertensive drugs that potentially improve the outcomes of antihypertensive users undergoing major surgeries, with the favorable regimens including RASis independent of the number of antihypertensive classes used.After undergoing all major surgery categories except CABG, patients on RASis were at a lower risk of death and functional decline than those who were treated with other antihypertensive classes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Health and Labour Sciences Research Grant (Grant No. Seisaku-Sitei-22AA2003 to KF) of the Japan Ministry of Health, Labour and Welfare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study protocol was approved by the ethics committee of Tokyo Medical and Dental University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.ACEiangiotensin-converting enzyme inhibitorAKIacute kidney injuryADLactivities of daily livingAHTacute hypertensionARBangiotensin II receptor blockerBMIbody mass indexCABGcoronary artery bypass graftingCCBcalcium channel blockerCIconfidence intervalsCKDchronic kidney diseaseCVDcardiovascular diseaseDMdiabetes mellitusDPCdiagnosis procedure combinationESKDend-stage kidney diseaseICD-10International Classification of Disease and Related Health Problems, 10th RevisionIQRinterquartile rangeMRAmineral corticoid receptor antagonistORodds ratioRASrenin–angiotensin systemRASirenin–angiotensin–aldosterone system inhibitorROSreactive oxygen speciesTHthiazide/thiazide-like diuretics